sur Relief Therapeutics Holding SA (ETR:RLF)
MindMaze Therapeutics Releases 2025 Annual Report and Strategic Update
MindMaze Therapeutics has announced the release of its 2025 Annual Report, focusing on key advancements in its neurotherapeutics platform. The Geneva-based company made significant strides in U.S. market expansion and reimbursement strategy, as evidenced by a collaboration with Vibra Healthcare and statistically significant improvements in patient outcomes.
The report highlights the commercial rollout of MindMaze's platform across various care settings. Appointing Zach Henderson as CEO, the company integrates clinical foundations with business strategies. A business combination with NeuroX marks a milestone, resulting in the realignment of MindMaze's operations toward precision neurotherapeutics.
Financially, MindMaze reported CHF 0.6 million in revenue against CHF 9.9 million net loss, reflecting investment in technology and commercial initiatives. For 2026, MindMaze aims to scale its U.S. operations, broaden application outlets, and establish significant partnerships to promote its platform further.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Relief Therapeutics Holding SA